Grelan Pharmaceutical Co., Ltd.

Aska Pharmaceuticals Co., Ltd.

Laboratoires Fournier S.c.a.

Nagatoshi Wagatsuma

Tomoji Aotsuka

Kouki Ishitani

Kentarou Kumazawa

Takashi Nose

Jean Louis Binet

Naoki Ashizawa

Christian Guffroy

Hideo Kato

Hirotaka Kasai

The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

PDE IV inhibitors

1,8-naphthyridin-2(1H)-one derivatives

Pyrazole derivatives and COX inhibitors containing them

2-ureido-benzamide derivatives

Growing community of inventors

Hamura, Japan

Nagatoshi Wagatsuma